Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

Official record

Identifier

NCT07333053

Recruiting locations

country

China

Interventions studied

Transarterial infusion chemotherapy (TAIC)Intravenous Chemotherapy（IVC）

Lead sponsor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Target enrolment

50 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Recruiting

First posted

Jan 12, 2026

Last updated on the registry

Sep 11, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Study population:

Patients who meet all inclusion criteria and none of the exclusion criteria are eligible for enrolment and study treatment.

Inclusion criteria:

1. Age ≥ 18 years old;
2. Histopathologically confirmed CRC adenocarcinoma;
3. Locally advanced CRC confirmed as clinical T4 stage on CT/MRI imaging, with or without synchronous liver metastases;
4. For patients with CRLM, hepatic tumor burden shall be lower than the burden of the primary colorectal lesion. Consequently, the multidisciplinary team (MDT) agree by consensus that CRC should be a priority target for treatment.
5. No prior administration of chemotherapy, targeted therapy or radiotherapy for the current malignancy;
6. Adequate haematological, heart, liver and renal functions are required, with the following specific criteria: white blood cell count≥4×109 /L, neutrophils≥1.5×109 /L, platelets≥100×10⁹ /L, haemoglobin≥100 g/L, total bilirubin≤34.2 μmol/L, aspartate aminotransferase≤100 IU/L, alanine aminotransferase≤100 IU/L, serum creatinine ≤133 μmol/L or creatinine clearance rate≥60 mL/min, and urine protein/creatinine\<1;
7. Estimated survival is more than 3 months;
8. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2;
9. All the patients in this study are required to sign an informed consent form.

Exclusion criteria:

1. Patients have other primary malignant tumors;
2. Patients with recurrent CRC;
3. Patients with distant metastases besides synchronous hepatic metastases (e.g., pulmonary, bone, or brain metastases);
4. For patients with CRLM, the MDT consensus recommends a liver-first treatment strategy to avoid the risk of rapid hepatic lesion progression;
5. CRC patients with gastrointestinal perforation
6. Patients with malignant bowel obstruction refractory to conservative management;
7. Patients are allergic to the antitumor agents;
8. Women pregnant, breastfeeding or planning to become pregnant;
9. Patients receiving other antitumor therapies, such as chemotherapy, targeted therapy or radiotherapy;
10. Patients with MSI-H/dMMR CRC.

Indexed under

Colorectal Cancer